Comparison of the effect of oral clonidine premedication with placebo on perioperative blood loss in total hip arthroplasty surgery patients

Effect of oral clonidine premedication on perioperative blood loss in elective primary total hip arthroplasty.

A randomized controlled, double blinded clinical trial with parallel groups, on 34 patients. Randomization is done by the block randomization concealed in sequentially numbered, opaque, sealed envelopes.

Trial participants, investigators, healthcare providers for participants and outcome assessors are kept blind. Patients are randomly divided into two groups of 17. 90 minutes before surgery, the intervention group receives 0.2 mg clonidine tablets and the control group a placebo tablet. During operation, mean blood pressure is kept 70-80 mm Hg. The total amount of bleeding is measured by weight of blood gases, blood in suction bottle and around the operative site. Transfusion is done if the bleeding rate exceeds the allowable blood loss or if the patient develops hemodynamic instability and the amount is recorded. After surgery, hemoglobin is measured on the first and third day and transfusion rate is recorded.

ASA class 1 and 2 patients between 18 and 75 years scheduled for unilateral elective primary total hip arthroplasty are enrolled. Patients with ASA class 3 and 4, BMI> 30, hemoglobin<10, severe liver and kidney disease, coagulation disorder, alcoholics, taking anticoagulants, revision total hip arthroplasty or previous surgery in the operated area are excluded.

Patients in the clonidine group are given 0.2 mg oral clonidine and in the control group, a placebo tablet is given.

Intraoperative blood loss, postoperative hemoglobin level, blood transfusion rate.

To assign patients to two groups, randomization is done by the block randomization method and concealed in sequentially numbered, sealed, opaque envelopes. In order to maintain a random sequence, the envelopes are numbered in the same way on the outer surface. Then envelopes are glued and placed inside the box, respectively. At the time of the assignment, according to the order of entry of eligible participants into the study, the relevant enveloper is opened in order and the assigned group of that participant is revealed.

Participants, investigators, healthcare providers for participants and outcome assessors are kept blind.